Your browser doesn't support javascript.
loading
Contributions of Fasting and Postprandial Glucose Concentrations to Haemoglobin A1c in Drug-Naïve Mal-Glucose Metabolism in Chinese Population Using Continuous Glucose Monitoring System.
Yan, Rengna; Hu, Yun; Li, Fengfei; Jiang, Lanlan; Xu, Xiaohua; Wang, Jie; Zhang, Ying; Ye, Lei; Lee, Kok Onn; Su, Xiaofei; Ma, Jianhua.
Afiliación
  • Yan R; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Hu Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Li F; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Jiang L; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Xu X; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Wang J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Zhang Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Ye L; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore 169609.
  • Lee KO; Department of Medicine, National University of Singapore, Singapore 119228.
  • Su X; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
  • Ma J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Int J Endocrinol ; 2019: 1267475, 2019.
Article en En | MEDLINE | ID: mdl-31871450
ABSTRACT

AIM:

To clarify the contributions of fasting glucose (FG) and postprandial glucose (PG) to HbA1c in drug-naïve patients with type 2 diabetes (T2D) and impaired glucose tolerate (IGT)/impaired fasting glucose (IFG).

METHODS:

Continuous glucose monitoring (CGM) was performed in 305 drug-naïve Chinese patients with T2D or IGT/IFG. The incremental area under the curve (AUC) above a glucose value of 6.1 mmol/L or FG glucose levels were calculated to evaluate the contributions of PG or FG to HbA1c values.

RESULTS:

According to quintiles of HbA1c, T2D patients were divided into five groups (group 1 to 5), and patients with IGT/IFG were assigned into group 0. PG was the predominant contributor in the lower groups with HbA1c 4.9∼6.0% and 6.1∼7.8%. The relative contributions of FG and PG to HbA1c had no significance in the middle groups of HbA1c (7.9∼8.7% and 8.8∼9.5%). FG contributed significantly more than PG in the higher groups of HbA1c (9.6∼10.9% and 11.0∼14.6%). Regression analyses indicate that the contributions of FG and PG were equal (both 50%) when the level of HbA1c was 8.5%.

CONCLUSIONS:

In drug-naïve patients with T2D or IGT/IFG, PG contributed more in patients with HbA1c < 8.5%, whereas FG became the predominant contributor in the poorly controlled patients with HbA1c ≥ 8.5%. These results may help the health-care provider set appropriate plasma glucose testing goals with the expectation of achieving specific HbA1c values.

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Int J Endocrinol Año: 2019 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Int J Endocrinol Año: 2019 Tipo del documento: Article País de afiliación: China